CJC 1295 No DAC & Ipamorelin Blend – Protide Health USA

CJC 1295 & Ipamorelin Blend Overview

CJC 1295 No DAC and Ipamorelin is a dual-peptide research formulation combining a modified growth hormone-releasing hormone analogue with a selective growth hormone secretagogue receptor agonist.

Protide Health supplies the blend in:

• CJC-1295 No DAC 5mg / Ipamorelin 5mg
• CJC-1295 No DAC 10mg / Ipamorelin 10mg

Each formulation is supplied as white to off-white lyophilized research material in a 3mL vial.

The combination brings together two mechanistically distinct experimental pathways:

• CJC-1295 No DAC: GHRH receptor-associated signaling
• Ipamorelin: Ghrelin/GHS-R1a receptor-associated signaling

The blend is specified as 99% purity, HPLC-MS verified, and third-party tested for qualified laboratory investigation.

Technical Specifications

CJC-1295 No DAC

• Peptide Type: Synthetic modified GHRH analogue
• Peptide Length: 29 amino acids
• Molecular Formula: C152H252N44O42
• Molecular Weight: approximately 3367.90 g/mol
• PubChem CID: 91976842
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
• Common Names: CJC-1295 No DAC, Modified GRF(1-29), Mod GRF 1-29

Researchers can review the supplied CJC-1295 No DAC chemical structure.

Ipamorelin

• Peptide Type: Synthetic pentapeptide growth hormone secretagogue
• Molecular Formula: C38H49N9O5
• Molecular Weight: approximately 711.86 g/mol
• CAS Number: 170851-70-4
• PubChem CID: 9831659
• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
• Receptor Context: GHS-R1a / ghrelin receptor

Researchers can review the supplied Ipamorelin chemical structure.

Finished Blend

• Available Sizes: 5mg/5mg and 10mg/10mg
• Form: Lyophilized powder
• Vial Size: 3mL
• Purity: 99%
• Testing: HPLC-MS verified; third-party tested
• Appearance: White to off-white
• Solubility: Soluble in water
• Storage: Store sealed at ≤6°C and protected from heat, light, and moisture
• Research Use: GHRH-receptor, ghrelin-receptor, pituitary-signaling, biochemical, analytical, and qualified preclinical research only

CJC 1295 No DAC Identity Note

The term CJC 1295 is used inconsistently across commercial and chemical databases.

For this Protide Health product, the intended component is specifically:

CJC-1295 No DAC / Modified GRF(1-29)

The supplied PubChem record CID 91976842 supports:

• Formula C152H252N44O42
• Molecular weight approximately 3367.9 g/mol
• A 29-residue GHRH-derived peptide

However, public database synonym and CAS records for CJC-1295 can overlap between DAC-containing and No-DAC forms.

Because of this ambiguity, Protide Health should not rely on CAS 863288-34-0 alone as definitive proof of the No-DAC molecular identity.

The most useful identifiers for this product are:

• Verified 29-amino-acid sequence
• Molecular formula
• Molecular weight
• HPLC-MS data
• PubChem CID
• Lot-specific analytical documentation

What Is CJC 1295 Peptide?

The phrase CJC 1295 peptide can refer broadly to modified growth hormone-releasing hormone analogues.

Growth hormone-releasing hormone, or GHRH, is an endogenous hypothalamic peptide involved in regulation of pituitary growth hormone secretion.

Modified GRF(1-29) was designed from the biologically active N-terminal region of GHRH.

The No-DAC research peptide contains substitutions intended to improve resistance to enzymatic degradation relative to unmodified GRF(1-29).

Research involving CJC 1295 No DAC commonly investigates:

• GHRH receptor activation
• Pituitary signaling
• cAMP pathways
• Growth hormone secretion models
• GHRH analogue stability
• Peptide receptor pharmacology

CJC 1295 & GHRH Receptor Research

The GHRH receptor is a class B G protein-coupled receptor.

Experimental activation can involve:

• Gs protein signaling
• Adenylate cyclase
• Cyclic AMP
• Protein kinase A
• Pituitary somatotroph signaling
• Growth hormone release

This pathway is mechanistically different from the receptor targeted by Ipamorelin.

That distinction is important when examining a CJC 1295 Ipamorelin blend.

Ipamorelin Research Context

Ipamorelin is a synthetic pentapeptide with the sequence:

Aib-His-D-2-Nal-D-Phe-Lys-NH₂

It acts as a growth hormone secretagogue receptor agonist.

The receptor is commonly called:

• GHS-R1a
• Growth hormone secretagogue receptor
• Ghrelin receptor

Published experimental research identified Ipamorelin as a potent GH secretagogue with greater selectivity for growth hormone release than some earlier GHRP compounds under the conditions studied.

Research areas include:

• GHS-R1a signaling
• Pituitary GH release
• Ghrelin receptor pharmacology
• Growth hormone secretagogue selectivity
• Endocrine signaling

CJC 1295 Ipamorelin Research Rationale

The term CJC 1295 Ipamorelin refers to the pairing of two peptides acting through different receptor systems.

CJC-1295 No DAC

Primarily associated with:

GHRH receptor signaling

Ipamorelin

Primarily associated with:

GHS-R1a / ghrelin receptor signaling

Because both pathways can converge on pituitary growth hormone secretion, combined laboratory research can examine:

• Receptor pathway interactions
• Signal integration
• Pituitary responses
• Temporal signaling patterns
• Comparative secretagogue pharmacology

However, the existence of two complementary pathways does not automatically demonstrate synergy in the finished blend.

CJC 1295 With Ipamorelin

The phrase cjc 1295 with ipamorelin is frequently used for combined research formulations.

The scientific value of such models lies in studying two separate upstream endocrine signaling mechanisms.

GHRH receptor activation and GHS-R1a activation are not identical.

Their signaling can differ in:

• Receptor type
• Ligand structure
• Second-messenger pathways
• Temporal response
• Endocrine feedback

A controlled laboratory experiment should therefore distinguish the effects of each peptide from those of the combination.

CJC 1295 and Ipamorelin: Combination Research

The phrase cjc 1295 and ipamorelin refers to the same two-component research concept.

Useful experimental controls may include:

• CJC-1295 No DAC alone
• Ipamorelin alone
• Combined CJC-1295 No DAC + Ipamorelin
• Vehicle control
• Concentration-matched comparator groups

Without these controls, an observed response cannot be confidently attributed to:

• CJC-1295
• Ipamorelin
• Additive signaling
• A true synergistic interaction

Co-formulation by itself does not establish synergy.

CJC 1295 DAC vs No DAC

The phrase cjc 1295 dac is important because CJC terminology is often confused online.

“DAC” refers to a Drug Affinity Complex modification designed to enable covalent albumin association.

CJC-1295 With DAC

The classic DAC-containing CJC-1295 molecule incorporates a reactive chemical group designed to bind circulating albumin.

This markedly changes its pharmacokinetic behavior.

CJC-1295 No DAC

The No-DAC form does not contain the albumin-binding DAC modification.

It is commonly referred to commercially as:

• Modified GRF(1-29)
• Mod GRF 1-29
• CJC-1295 No DAC

These two compounds should not be considered analytically or pharmacokinetically interchangeable.

CJC 1295 With DAC Search Context

The phrase cjc 1295 with dac usually refers to the longer-acting albumin-binding CJC-1295 analogue.

That is not the intended identity of the CJC component in this blend.

The Protide Health formulation contains:

CJC-1295 No DAC / Modified GRF(1-29)

Researchers reviewing studies involving DAC-containing CJC-1295 should therefore not automatically transfer:

• Half-life data
• Exposure duration
• Pharmacokinetic findings
• Albumin-binding behavior
• Clinical protocol information

to this No-DAC formulation.

CJC 1295 Ipamorelin Dosage Search Context

The phrase cjc 1295 ipamorelin dosage generally concerns human administration.

Protide Health does not provide human dosing instructions.

The quantities on this page identify vial contents only.

5mg/5mg Blend

• CJC-1295 No DAC: 5mg
• Ipamorelin: 5mg
• Total peptide material: 10mg

10mg/10mg Blend

• CJC-1295 No DAC: 10mg
• Ipamorelin: 10mg
• Total peptide material: 20mg

These are not recommended human doses.

No instructions are provided for:

• Human injection
• Daily administration
• Nighttime administration
• Weekly schedules
• Treatment cycles
• Body-weight calculations
• Reconstitution for human administration
• Hormone optimization
• Athletic use

Laboratory concentrations should instead be selected according to assay design and validated experimental methodology.

CJC 1295 Side Effects Search Context

The phrase cjc 1295 side effects typically concerns human safety.

An important distinction must be made between:

• CJC-1295 with DAC clinical research
• Modified GRF(1-29) / No-DAC material
• Independently supplied research formulations
• Combination formulations containing Ipamorelin

Safety findings from one category do not automatically establish the safety profile of another.

Potential adverse events reported in clinical GH-axis secretagogue research cannot establish the human safety of this Protide Health product.

No claim is made that the blend is safe for human administration.

Ipamorelin Selectivity Research

One of the historically important Ipamorelin studies compared the peptide with earlier growth hormone secretagogues.

The study reported that Ipamorelin stimulated growth hormone release while showing comparatively little ACTH or cortisol stimulation under the experimental conditions tested.

This led the investigators to characterize Ipamorelin as the first selective GH secretagogue of its type.

That finding provides useful receptor-pharmacology context but does not establish a human-use protocol for this blend.

CJC 1295 vs Ipamorelin

CJC-1295 No DAC and Ipamorelin differ substantially.

CJC-1295 No DAC

• 29 amino acids
• GHRH-derived analogue
• GHRH receptor-associated signaling
• Molecular weight ~3367.9 g/mol

Ipamorelin

• 5 residues
• Synthetic growth hormone secretagogue
• GHS-R1a / ghrelin receptor agonist
• Molecular weight ~711.86 g/mol

The two peptides should therefore be considered complementary research tools rather than chemically similar compounds.

Growth Hormone Signaling Research

The blend may be useful in qualified laboratory models examining signaling upstream of pituitary growth hormone secretion.

Potential areas include:

• GHRH receptor biology
• GHS-R1a biology
• Somatotroph signaling
• cAMP-related pathways
• Secretagogue pharmacology
• Endocrine feedback systems
• Receptor cross-talk

Results should be interpreted according to the experimental model used.

Animal or cell findings cannot automatically establish human outcomes.

CJC 1295 No DAC & Pharmacokinetic Distinction

Removing the DAC functionality changes a key aspect of CJC research.

A DAC-containing molecule is specifically designed for prolonged albumin association.

Modified GRF(1-29) lacks that affinity complex.

Researchers should therefore avoid using DAC-containing CJC pharmacokinetic data as though it directly described the No-DAC material.

This distinction is especially important when interpreting search results simply labeled CJC 1295.

Research Blend Design

A properly controlled study of the blend should ideally separate:

1. CJC-1295 No DAC effects
2. Ipamorelin effects
3. Combined effects
4. Vehicle effects

Possible endpoints could include:

• Receptor activation
• Second-messenger signaling
• Hormone secretion in validated models
• Time-dependent signaling
• Dose-response relationships
• Receptor-antagonist experiments

This allows researchers to distinguish simple co-activity from true interaction.

Related Protide Health Research Products

Researchers comparing other multi-peptide formulations may review the Semax + Selank N-Acetyl Amidate Blend for a mechanistically distinct neuropeptide research system.

The Klow Blend GHK-Cu + KPV + BPC-157 + TB-500 provides a separate multi-component formulation centered on copper-peptide, epithelial, vascular, and cytoskeletal research.

Researchers may also examine the Illumineuro Einstein Peptide Blend for another distinct multi-peptide experimental model.

These products should not be considered interchangeable with the CJC 1295 Ipamorelin blend.

Research Format & Storage

Protide Health supplies the blend in:

5mg/5mg

• CJC-1295 No DAC: 5mg
• Ipamorelin: 5mg
• Total: 10mg

10mg/10mg

• CJC-1295 No DAC: 10mg
• Ipamorelin: 10mg
• Total: 20mg

Product specifications include:

• Form: Lyophilized powder
• Vial Size: 3mL
• Purity: 99%
• Testing: HPLC-MS verified
• Verification: Third-party tested
• Appearance: White to off-white
• Solubility: Soluble in water

Storage specifications:

• Store at ≤6°C
• Keep sealed
• Protect from heat
• Protect from direct light
• Protect from moisture

These statements describe laboratory storage only.

Research Limitations

Several limitations should be considered when interpreting CJC 1295 and Ipamorelin research:

• The blend contains two chemically and mechanistically distinct peptides.
• CJC-1295 terminology is inconsistent across databases and commercial sources.
• Public CAS records for DAC and No-DAC variants can overlap or conflict.
• Sequence and analytical data are more useful than CAS alone for distinguishing No-DAC material.
• Findings involving CJC-1295 with DAC cannot automatically be applied to Modified GRF(1-29).
• Ipamorelin findings cannot automatically be attributed to the combination.
• Co-formulation does not establish biological synergy.
• Much of the mechanistic evidence comes from experimental or preclinical research.
• Clinical secretagogue findings do not establish human safety of independently supplied laboratory material.
• The 5mg/5mg and 10mg/10mg quantities represent vial contents, not human doses.
• Protide Health material is not an FDA-approved pharmaceutical formulation.

For these reasons, the blend is supplied strictly for qualified laboratory research.

Literature & Citation Index

Ipamorelin, the First Selective Growth Hormone Secretagogue

Year: 1998
PMID: 9849822
DOI: 10.1530/eje.0.1390552
Research Context: Ipamorelin, growth hormone secretagogue receptor pharmacology, pituitary GH release, ACTH/cortisol selectivity, and comparative GHRP research.

GHRH & Growth Hormone Secretagogue Research

The broader scientific literature includes extensive work examining:

• GHRH receptor signaling
• Modified GHRH analogues
• Ghrelin/GHS-R1a signaling
• Growth hormone secretagogues
• Pituitary endocrine physiology

Researchers can review broader CJC-1295, Modified GRF(1-29), Ipamorelin, GHRH and GHS-R1a literature indexed by PubMed.

Frequently Asked Questions

What is CJC 1295?

CJC 1295 is a name used for modified GHRH analogues. This Protide Health blend specifically uses the No-DAC / Modified GRF(1-29) form.

What is CJC 1295 peptide?

The CJC 1295 peptide in this formulation is a synthetic 29-amino-acid GHRH analogue intended for GHRH-receptor research.

What does CJC 1295 Ipamorelin contain?

The product contains:

• CJC-1295 No DAC
• Ipamorelin

in equal mg quantities.

What sizes are available?

Protide Health supplies:

• 5mg/5mg
• 10mg/10mg

What is the CJC-1295 No DAC sequence?

The specified sequence is:

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

What is the Ipamorelin sequence?

The sequence is:

Aib-His-D-2-Nal-D-Phe-Lys-NH₂

What is the difference between CJC 1295 DAC and No DAC?

The DAC form incorporates an albumin-binding Drug Affinity Complex, while the No-DAC form does not. This difference substantially affects molecular identity and pharmacokinetic behavior.

Is CJC 1295 with DAC the same as this product?

No. This blend is specified as CJC-1295 No DAC / Modified GRF(1-29).

What does CJC 1295 with Ipamorelin research investigate?

Research can examine combined GHRH-receptor and GHS-R1a signaling, pituitary secretagogue pathways, receptor interactions, and endocrine signaling models.

What is CJC 1295 Ipamorelin dosage?

Protide Health does not provide human cjc 1295 ipamorelin dosage instructions. The 5mg/5mg and 10mg/10mg values describe vial contents only.

What are CJC 1295 side effects?

Human safety cannot be established from this laboratory product. Safety observations from clinical CJC or secretagogue research do not automatically apply to this blend.

Is Ipamorelin a GHRH analogue?

No. Ipamorelin is a GHS-R1a/ghrelin-receptor agonist, whereas CJC-1295 No DAC acts through the GHRH receptor system.

Do CJC 1295 and Ipamorelin work synergistically?

The two compounds act through distinct receptor systems, but co-formulation alone does not establish synergy. Controlled experiments are required to demonstrate an interaction.

What purity does Protide Health specify?

Protide Health specifies 99% purity, HPLC-MS verification, and third-party testing.

Is this blend intended for human use?

No. It is supplied exclusively for GHRH-receptor, GHS-R1a, pituitary-signaling, biochemical, molecular, analytical, in-vitro, and qualified preclinical research.

Laboratory Terms & Compliance

Laboratory Research Use Only

This CJC 1295 No DAC and Ipamorelin blend is supplied exclusively for laboratory research, GHRH-receptor studies, GHS-R1a research, pituitary-signaling investigation, analytical testing, biochemical experimentation, molecular studies, in-vitro research, and qualified preclinical experimentation.

It is not intended for human or veterinary consumption, medical use, hormone treatment, bodybuilding, athletic-performance enhancement, weight-loss treatment, injection, diagnostic use, therapeutic use, or clinical administration.

No human dosage, injection schedule, nighttime protocol, treatment cycle, body-weight calculation, hormone-optimization plan, reconstitution instructions for human administration, or clinical guidance is provided.

The purchaser is responsible for appropriate laboratory handling, storage, and use under applicable institutional, federal, state, and local requirements.

For research use only.